MétaCan
Menu
Back to cohort
Record W2918322716 · doi:10.1002/cncr.32004

Critical questions in ovarian cancer research and treatment: Report of an American Association for Cancer Research Special Conference

2019· article· en· W2918322716 on OpenAlexaff
Robert C. Bast, Ursula A. Matulonis, Anil K. Sood, Ahmed A. Ahmed, Adaobi E. Amobi, Frances R. Balkwill, M. Wielgos‐Bonvallet, David D.L. Bowtell, James D. Brenton, Joan S. Brugge, Robert L. Coleman, Giulio Draetta, Kai Doberstein, Ronny Drapkin, Mark A. Eckert, Robert P. Edwards, Kevin M. Elias, Darren Ennis, P. Andrew Futreal, David M. Gershenson, Roger A. Greenberg, David G. Huntsman, Jennifer X. Ji, Elise C. Kohn, Claudia Iavarone, Ernst Lengyel, Douglas A. Levine, Christopher J. Lord, Zhen Lü, Gordon B. Mills, Francesmary Modugno, Brad H. Nelson, Kunle Odunsi, Jessica A. Pilsworth, Robert Rottapel, Daniel J. Powell, Li Shen, Ie‐Ming Shih, David R. Spriggs, Josephine Walton, Kaiyang Zhang, Rugang Zhang, Lee Zou

Bibliographic record

VenueCancer · 2019
Typearticle
Languageen
FieldMedicine
TopicPARP inhibition in cancer therapy
Canadian institutionsUniversity of TorontoBC Cancer AgencyUniversity of British Columbia
FundersEunice Kennedy Shriver National Institute of Child Health and Human DevelopmentNational Cancer Institute, Cairo UniversityNational Cancer InstituteCancer Research UKProspect Creek FoundationOvarian Cancer Research FoundationDr. Miriam and Sheldon G. Adelson Medical Research FoundationBreast Cancer Research FoundationCancer Prevention and Research Institute of TexasAmerican Cancer Society
KeywordsMedicineOvarian cancerDiseaseCancerChemotherapyImmunotherapyOncologyTranslational researchInternal medicineIntensive care medicinePathology

Abstract

fetched live from OpenAlex

Substantial progress has been made in understanding ovarian cancer at the molecular and cellular level. Significant improvement in 5-year survival has been achieved through cytoreductive surgery, combination platinum-based chemotherapy, and more effective treatment of recurrent cancer, and there are now more than 280,000 ovarian cancer survivors in the United States. Despite these advances, long-term survival in late-stage disease has improved little over the last 4 decades. Poor outcomes relate, in part, to late stage at initial diagnosis, intrinsic drug resistance, and the persistence of dormant drug-resistant cancer cells after primary surgery and chemotherapy. Our ability to accelerate progress in the clinic will depend on the ability to answer several critical questions regarding this disease. To assess current answers, an American Association for Cancer Research Special Conference on "Critical Questions in Ovarian Cancer Research and Treatment" was held in Pittsburgh, Pennsylvania, on October 1-3, 2017. Although clinical, translational, and basic investigators conducted much of the discussion, advocates participated in the meeting, and many presentations were directly relevant to patient care, including treatment with poly adenosine diphosphate ribose polymerase (PARP) inhibitors, attempts to improve immunotherapy by overcoming the immune suppressive effects of the microenvironment, and a better understanding of the heterogeneity of the disease.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.000
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesInsufficient payload (model declined to judge)
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.270
Threshold uncertainty score1.000

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0010.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.001
Science and technology studies0.0000.001
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0010.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.198
GPT teacher head0.544
Teacher spread0.346 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations54
Published2019
Admission routes1
Has abstractyes

Explore more

Same venueCancerSame topicPARP inhibition in cancer therapyFrench-language works237,207